Table 1.
Cells locomoting (%)
|
Time locomoting (%)
|
|||
---|---|---|---|---|
Control | mAb | Control | mAb | |
α2 (1) | 83 ± 4 | 28 ± 7*** | 38 ± 3 | 20 ± 2*** |
α2 (2) | 88 ± 14 | 58 ± 13*** | 46 ± 7 | 36 ± 7** |
α2 (1, 2) | 88 ± 14 | 27 ± 4*** | 46 ± 7 | 30 ± 4*** |
α2 (1, 2) + α3 | 93 ± 5 | 30 ± 8*** | 48 ± 8 | 24 ± 3*** |
α2 (1, 2) + αv | 97 ± 1 | 40 ± 9*** | 50 ± 4 | 34 ± 7*** |
α2 (1, 2) + α3 + αv | 97 ± 1 | 38 ± 1*** | 50 ± 4 | 28 ± 5*** |
α2 (1, 2) + α3 + α5 + α6 + αv | 93 ± 6 | 46 ± 18*** | 45 ± 8 | 26 ± 4*** |
α3 | 88 ± 14 | 86 ± 13 | 46 ± 7 | 48 ± 7 |
αv | 88 ± 14 | 95 ± 5 | 46 ± 7 | 45 ± 5 |
β1 | 88 ± 3 | 23 ± 5*** | 39 ± 3 | 17 ± 4*** |
Cells were preincubated with mAbs (10 μg/ml), and mAbs were additionally added to the medium during and after polymerization of the collagen matrix. Steady-state locomotion was observed for at least 15 h and calculated from single-cell analysis as cumulative percentage of cells locomoting and time locomoting (means of three independent experiments ± SD). Significant differences of mAb treatment versus control cells are indicated by asterisks (** P < 0.001, *** P < 0.0001). mAbs: α2 (1), 6F1; α2 (2), P1E6; α3, P1B5; α5, SAM-1; α6, GoH3; αv, 17E6; β1, 4B4.